Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Lowered by Wall Street Zen

Key Points

• Entrada Therapeutics was downgraded from a "hold" rating to a "sell" rating by Wall Street Zen, indicating a bearish outlook from analysts.
• Despite the downgrade, HC Wainwright maintains a "buy" rating with a target price of $20.00 for Entrada shares, highlighting a mixed analyst sentiment on the stock.
• Entrada Therapeutics reported a significant earnings miss, with a loss of ($1.04) EPS and revenue of only $1.98 million, falling short of analysts' expectations of $8.17 million.

Wall Street Zen cut shares of Entrada Therapeutics (NASDAQ:TRDA - Free Report) from a hold rating to a sell rating in a report released on Saturday morning.

Separately, HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research note on Tuesday, May 20th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Entrada Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.67.

Entrada Therapeutics Trading Up 4.8%

Shares of NASDAQ:TRDA traded up $0.25 on Friday, hitting $5.41. The company had a trading volume of 41,329 shares, compared to its average volume of 147,716. The stock has a 50 day moving average price of $6.78 and a 200 day moving average price of $8.88. Entrada Therapeutics has a 1-year low of $4.93 and a 1-year high of $21.79. The stock has a market cap of $205.68 million, a price-to-earnings ratio of -3.04 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.18). Entrada Therapeutics had a negative net margin of 92.30% and a negative return on equity of 17.81%. The business had revenue of $1.98 million during the quarter, compared to analyst estimates of $8.17 million. Sell-side analysts anticipate that Entrada Therapeutics will post 1.12 earnings per share for the current fiscal year.

Insider Transactions at Entrada Therapeutics

In other Entrada Therapeutics news, Director Kush Parmar sold 27,000 shares of the stock in a transaction dated Wednesday, July 9th. The shares were sold at an average price of $7.50, for a total transaction of $202,500.00. Following the sale, the director directly owned 1,093,313 shares in the company, valued at $8,199,847.50. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Ventures V. L.P. 5Am sold 6,935 shares of the stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $7.50, for a total transaction of $52,012.50. Following the sale, the insider owned 1,093,313 shares in the company, valued at $8,199,847.50. The trade was a 0.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 254,000 shares of company stock worth $1,782,000 over the last quarter. Corporate insiders own 7.59% of the company's stock.

Institutional Investors Weigh In On Entrada Therapeutics

A number of large investors have recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Entrada Therapeutics in the 4th quarter valued at approximately $36,000. BNP Paribas Financial Markets acquired a new stake in shares of Entrada Therapeutics in the 4th quarter valued at approximately $57,000. Virtus ETF Advisers LLC acquired a new stake in shares of Entrada Therapeutics in the 4th quarter valued at approximately $68,000. Russell Investments Group Ltd. boosted its stake in shares of Entrada Therapeutics by 53,455.6% in the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock valued at $83,000 after purchasing an additional 4,811 shares in the last quarter. Finally, State of Wyoming acquired a new stake in shares of Entrada Therapeutics in the 4th quarter valued at approximately $104,000. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.